{"id":"W3045653281","doi":"10.1080/10428194.2020.1795161","title":"Prolonged progression free survival in a subset of responders to the combination of brentuximab vedotin and bendamustine in heavily treated patients with relapsed or refractory Hodgkin lymphoma: updated results from an international multi-center phase I/II experience","year":2020,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Spinal Cord Injury BC; Princess Margaret Cancer Centre; University of Toronto","funders":"H. Lundbeck A/S; Seattle Genetics; AstraZeneca","keywords":"Brentuximab vedotin; Bendamustine; Medicine; Oncology; Internal medicine; Refractory (planetary science); Lymphoma; Malignancy; Hodgkin lymphoma; Biology; Rituximab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003420538,0.0002005809,0.0004762232,0.0001859775,0.0002422026,0.0004050732,0.0002761218,0.0005409456,0.0009906099],"category_scores_gemma":[0.0008027087,0.0000743124,0.0002673581,0.0002840775,0.0001421406,0.0003139563,0.0001262891,0.0006297568,0.0002480969],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004427702,"about_ca_system_score_gemma":0.0002422015,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006062511,"about_ca_topic_score_gemma":0.002026125,"domain_scores_codex":[0.9998276,0.00006130854,0.00001494191,0.00002579064,0.00003054296,0.00003984274],"domain_scores_gemma":[0.9995647,0.0001910239,0.00007182928,0.00001933297,0.00003437271,0.0001187249],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.02765188,0.00142813,0.401232,0.000450029,0.000349464,0.01843738,0.0006745719,0.00253877,0.0280329,0.0005497961,0.04527959,0.4733755],"study_design_scores_gemma":[0.003785018,0.02333825,0.8641502,0.0002912865,0.0008361125,0.04017957,0.0005361479,0.004776821,0.004787419,0.001700115,0.05553882,0.00008011686],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9697683,0.01130204,0.0005773967,0.009290824,0.000382215,0.00007898412,0.0006605368,0.00005633667,0.007883505],"genre_scores_gemma":[0.9879547,0.003512317,0.0004709103,0.004849822,0.000570338,0.00005689872,0.0009571019,0.00001423786,0.001613615],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0009906099,"threshold_uncertainty_score":0.003313899,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02072232746893428,"score_gpt":0.2885611615219742,"score_spread":0.2678388340530399,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}